id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-352557-l7sahv5t	Takla, Michael	Chloroquine, hydroxychloroquine, and COVID-19: systematic review and narrative synthesis of efficacy and safety	2020-11-13		.txt	text/plain	7587	347	43	In contrast, only 58% of observational studies employing an endpoint specific to efficacy recorded no significant difference in the attainment of outcomes, such as duration of hospital stay, need for mechanical ventilation, and probability of transfer to an intensive care unit (ICU), between COVID-19 patients given a range of CQ and/or HCQ doses, and the control groups. Indeed, of the remaining papers, 60% found evidence of a higher probability of discharge rate (Sbidian et al., 2020) , viral clearance and shorter symptom duration (Huang et al., 2020a) in a therapeutic context, and a lower incidence of SARS-CoV-2 infection in a prophylactic context (Bhattacharya et al., 2020 Although 60% of clinical trials found evidence of higher mild adverse drug-related events in the treatment group, none of those specifically focusing on cardiac-side effects discovered any significant difference relative to the control.	./cache/cord-352557-l7sahv5t.txt	./txt/cord-352557-l7sahv5t.txt